Original articleControlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis
References (14)
Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa — Third Investigation: The effect of an initial streptomycin supplement
Tubercle
(1966)Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa — Fifth investigation
Tubercle
(1970)Tuberculosis in Kenya: Follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey
Tubercle
(1979)The modern management and therapy of pulmonary tuberculosis
Comparative trial of isoniazid in combination with thiacetazone or a subtituted diphenylthiourea (SU 1906) or PAS in the treatment of acute pulmonary tuberculosis in East Africans
Tubercle
(1960)- et al.
Mycobacteria: Isolation, identification and sensitivity testing
(1968) Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain
Tubercle
(1973)
Cited by (41)
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis
2017, The Lancet Infectious DiseasesCitation Excerpt :We added these newly identified articles to the 32 trials and ten cohorts identified for the previous review. The characteristics of the 33 trials7,12–43 and 19 cohort studies44–62 are summarised in the appendix. In seven of the cohort studies and 28 of the trials, data for patients with active drug-susceptible tuberculosis were also reported.
Treatment outcome of patients with isoniazid mono-resistant tuberculosis
2015, Clinical Microbiology and InfectionCitation Excerpt :Hence, the Clinical and Laboratory Standards Institute suggests testing at two concentrations of isoniazid, because patients with low-level isoniazid resistance may benefit from continuing therapy with isoniazid [19]. However, several studies have shown that a four-drug 6-month short-course therapy with/without isoniazid can be similarly efficacious in treating isoniazid-resistant TB [2,4,5,20–22]. The present study also revealed that regimens with/without isoniazid have similar treatment success rates not only among patients with low-level isoniazid-resistant TB but also among those with high-level resistance.
Tuberculosis and Atypical Mycobacterial Infections
2011, Tropical Infectious Diseases: Principles, Pathogens and PracticeTuberculosis and Atypical Mycobacterial Infections
2011, Tropical Infectious DiseasesIsoniazid-resistant tuberculosis in Denmark: Mutations, transmission and treatment outcome
2010, Journal of InfectionCitation Excerpt :In the present study, the most common treatment regimens used were either modified standard HREZ daily therapy given 6–9 months as 3RE(H)Z/3-6RE(Z) or REZ supplemented with a Q. Individualized treatment regimens were constructed for patients with H polyresistance according to DST results. A previous trial has shown that a 6-month daily short-course HREZ therapy throughout could be used in H-monoresistant and H-polyresistant cases.6 However, 6 months REZ therapy without H was nearly as efficacious, which is recommended by the Centers for Disease Control and Prevention (CDC) in the presence of H resistance.23,24 A clinical trial on regimens for H-resistant cases comparing the duration of 6 or 9 months REZS, where ZS were given for the first two months of therapy showed low relapse rates and no relapses in the 9 month series, which has lead to existing recommendations of 6–9 months REZ therapy by the WHO.3,25 For patients with extensive disease WHO suggests that additional Q may strengthen the regimen.3 Recent promising evidence supports the use of the newer Q′s such as moxifloxacin in treatment regimens as opposed to the older Q′s and may be equally efficacious to H when substituted in the initial 2-month phase of standard therapy of susceptible TB with REZ.26,27 The role of supplementary Q′s for the treatment of H-resistant TB still remains to be determined. The critical concentration of a drug is defined as the lowest concentration that inhibits the growth of 95% “wild-type” strains of MTB that have not been exposed to the drug, and that simultaneously does not inhibit strains of MTB considered resistant that are isolated from patients not responding to therapy.17 The CLSI suggests testing at an additional higher concentration of H, may provide physicians with information about the level of drug resistance, helpful in making decisions on treatment regimens.
Tuberculosis and other mycobacterial infections
2010, Antibiotic and Chemotherapy: Expert Consult